{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:40:43Z","timestamp":1790800843517,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:p>Currently, various immunosuppressive drugs are used in organ transplantation. In particular, antithymoglobulin is a widely used drug in kidney transplantation in Korea, accounting for 20% of all induction therapy. According to existing studies, antithymoglobulin induction therapy has several advantages and disadvantages compared with other immunotherapies depending on the kidney transplant situation (dead donor, living donor, low-risk recipient, and high-risk recipient) or antithymoglobulin dose. In this review, we summarize the research conducted so far on antithymoglobulin and hope that antithymoglobulin research on kidney transplantation will be actively conducted in the future.<\/jats:p>","DOI":"10.1097\/md.0000000000037242","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T01:03:42Z","timestamp":1709341422000},"page":"e37242","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Current use of antithymoglobulin as induction regimen in kidney transplantation: A review"],"prefix":"10.1097","volume":"103","author":[{"given":"Byung Hwa","family":"Park","sequence":"first","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Na","family":"Kim","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-4541","authenticated-orcid":false,"given":"Ho Sik","family":"Shin","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonsoon","family":"Jung","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hark","family":"Rim","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5124\/jkma.2020.63.5.241","article-title":"History of organ transplantation and the development of key immunosuppressants.","volume":"63","author":"Rhu","year":"2020","journal-title":"J Korean Med Assoc"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1399-0012.2009.01127.x","article-title":"A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with thymoglobulin in living-donor kidney transplantation.","volume":"24","author":"Woodle","year":"2010","journal-title":"Clin Transplant"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"F525","DOI":"10.1152\/ajprenal.2000.279.3.F525","article-title":"Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice.","volume":"279","author":"Rabb","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 2","key":"R6-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ajt.15274","article-title":"OPTN\/SRTR 2017 annual data report: kidney.","volume":"19","author":"Hart","year":"2019","journal-title":"Am J Transplant"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trre.2016.02.002","article-title":"Immunological risk assessment: the key to individualized immunosuppression after kidney transplantation.","volume":"30","author":"Pratschke","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation.","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4285\/jkstn.2019.33.4.118","article-title":"Comparison of clinical outcomes of deceased donor kidney transplantations, with a focus on three induction therapies.","volume":"33","author":"Jeong","year":"2019","journal-title":"Korean J Transplant"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/jcm9051320","article-title":"Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation.","volume":"9","author":"Kim","year":"2020","journal-title":"J Clin Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(99)70414-2","article-title":"Incidence and long-term cost of steroid-related side effects after renal transplantation.","volume":"33","author":"Veenstra","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"R12-20250504","first-page":"CD005632","article-title":"Steroid avoidance or withdrawal for kidney transplant recipients.","volume":"2016","author":"Haller","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ekir.2021.11.028","article-title":"A randomized controlled trial on safety of steroid avoidance in immunologically low-risk kidney transplant recipients.","volume":"7","author":"Ekberg","year":"2022","journal-title":"Kidney Int Rep"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.intimp.2011.07.012","article-title":"Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.","volume":"11","author":"Liborio","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s13063-015-0891-y","article-title":"Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants.","volume":"16","author":"Lentine","year":"2015","journal-title":"Trials"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.transproceed.2011.01.035","article-title":"Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.","volume":"43","author":"Laftavi","year":"2011","journal-title":"Transplant Proc"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4285\/jkstn.2016.30.2.82","article-title":"Optimal dose of thymoglobulin for induction therapy in high risk kidney transplant recipients.","volume":"30","author":"Kim","year":"2016","journal-title":"J Korean Soc Transplant"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e104408","DOI":"10.1371\/journal.pone.0104408","article-title":"Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study.","volume":"9","author":"Grafals","year":"2014","journal-title":"PLoS One"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1600-6143.2010.03093.x","article-title":"Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies.","volume":"10","author":"Bachler","year":"2010","journal-title":"Am J Transplant"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00007890-200209270-00005","article-title":"Protective effect of T cell depletion in murine renal ischemia-reperfusion injury.","volume":"74","author":"Yokota","year":"2002","journal-title":"Transplantation"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1046\/j.1523-1755.2001.00944.x","article-title":"Anti-B7-1 blocks mononuclear cell adherence in vasa recta after ischemia.","volume":"60","author":"De Greef","year":"2001","journal-title":"Kidney Int"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.transproceed.2013.01.027","article-title":"Outcomes of living donor renal transplants with a negative cross-match and pretransplant donor-specific antibody.","volume":"45","author":"Knight","year":"2013","journal-title":"Transplant Proc"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1038\/s41598-021-84977-1","article-title":"Safety and effectiveness of kidney transplantation using a donation after brain death donor with acute kidney injury: a retrospective cohort study.","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"623","DOI":"10.23876\/j.krcp.21.310","article-title":"Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry.","volume":"41","author":"Lee","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e14582","DOI":"10.1111\/ctr.14582","article-title":"Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation.","volume":"36","author":"Mehta","year":"2022","journal-title":"Clin Transplant"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1159\/000351643","article-title":"Thymoglobulin and its use in renal transplantation: a review.","volume":"37","author":"Thiyagarajan","year":"2013","journal-title":"Am J Nephrol"},{"key":"R28-20250504","first-page":"1601","article-title":"Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects.","volume":"32","author":"Bamoulid","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.tp.0000215178.72344.9d","article-title":"Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data.","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200969110-00007","article-title":"Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.","volume":"69","author":"Deeks","year":"2009","journal-title":"Drugs"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/00007890-200109270-00012","article-title":"Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression.","volume":"72","author":"Mourad","year":"2001","journal-title":"Transplantation"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:13:38Z","timestamp":1746328418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037242","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}